Edition:
India

Avenue Therapeutics Inc (ATXI.OQ)

ATXI.OQ on NASDAQ Stock Exchange Capital Market

5.04USD
23 Feb 2018
Change (% chg)

$0.09 (+1.82%)
Prev Close
$4.95
Open
$4.97
Day's High
$5.05
Day's Low
$4.97
Volume
2,040
Avg. Vol
8,326
52-wk High
$8.56
52-wk Low
$3.40

Latest Key Developments (Source: Significant Developments)

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Avenue Therapeutics reports Q3 loss per share $0.30
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.30.  Full Article

Avenue therapeutics reports Q2 loss per share $0.70
Friday, 11 Aug 2017 

Aug 11 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics reports second quarter 2017 financial results and recent corporate highlights.Q2 loss per share $0.70.  Full Article

Avenue Therapeutics ic files for IPO of up to $50 mln
Monday, 22 May 2017 

May 22 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics Inc files for IPO of up to $50 million - sec filing.Avenue Therapeutics Inc - expect the public offering price to be between $9.00 and $11.00 per share.Avenue Therapeutics Inc - have applied to list our common stock on the nasdaq capital market under the symbol “atxi.”.Avenue Therapeutics Inc - raymond james, national securities corporation are underwriters to the ipo.Avenue Therapeutics Inc - ipo price is estimated solely for the purpose of computing the amount of the registration fee.  Full Article

BRIEF-Avenue Therapeutics reports Q3 loss per share $0.30

* Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights

No consensus analysis data available.